Amgen will report its latest earnings this Tuesday afternoon. The market expects the biotech company's revenue to grow 2.4% year on year, a slowdown from the 9.4% increase recorded in the same quarter last year. Last quarter, Amgen beat analysts' revenue expectations, reporting revenues of $8.62 billion, up 5.8% year on year. Analysts have generally reconfirmed their estimates over the last 30 days. Amgen shares are up 5.7% over the last month and head into earnings with an average analyst price target of $357.03 compared to the current share price of $386.80.
Amgen IncEarnings report upcoming; revenue growth expected to slow, but prior beat and price target above current price.